Comprehensive Review of COVID-19 on Benign Prostate Hyperplasia Patient Symptoms
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Since the outbreak of the global Coronavirus disease (COVID-19) pandemic in 2019, the number of confirmed cases has increased steadily worldwide. The most common symptom of COVID-19 (SARS-CoV-2) is respiratory symptoms. On the other hand, increased voiding frequency and lower urinary tract symptoms (LUTS) have also been reported. Regarding the relationship between LUTS and COVID-19, only small size (n<100) retrospective studies have been reported, but the post-International Prostate Symptom Score (IPSS) increases compared to pre-IPSS after a COVID-19 infection in those older than 50 years. α-blockers and phosphodiesterase-5 inhibitors are relatively safe, but there are conflicting reports on 5α-reductase inhibitors; hence, further research is needed. Four major theories have been argued regarding the relationship between LUTS and COVID-19: renin-angiotensin system-related, androgen-related, inflammation-related, and metabolic derangement-related. In conclusion, elderly male patients often have benign prostate hyperplasia as a co-morbidity, and the severity of COVID-19 is high in this group. Therefore, voiding symptoms in these patient groups is of particular concern.
Abstract
Since the outbreak of the global Coronavirus disease (COVID-19) pandemic in 2019, the number of confirmed cases has increased steadily worldwide. The most common symptom of COVID-19 (SARS-CoV-2) is respiratory symptoms. On the other hand, increased voiding frequency and lower urinary tract symptoms (LUTS) have also been reported. Regarding the relationship between LUTS and COVID-19, only small size (n<100) retrospective studies have been reported, but the post-International Prostate Symptom Score (IPSS) increases compared to pre-IPSS after a COVID-19 infection in those older than 50 years. α-blockers and phosphodiesterase-5 inhibitors are relatively safe, but there are conflicting reports on 5α-reductase inhibitors; hence, further research is needed. Four major theories have been argued regarding the relationship between LUTS and COVID-19: renin-angiotensin system-related, androgen-related, inflammation-related, and metabolic derangement-related. In conclusion, elderly male patients often have benign prostate hyperplasia as a co-morbidity, and the severity of COVID-19 is high in this group. Therefore, voiding symptoms in these patient groups is of particular concern.
참고문헌 (28)
- Haghpanah A, "Is COVID-19 a risk factor for progression of benign prostatic hyperplasia and exacerbation of its related symptoms? : a systematic review", Prostate Cancer Prostatic Dis, 25, pp.27~38 (2022)
- Wang D, "Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China", JAMA, 323, pp.1061~1069 (2021)
- Gu J, "COVID-19 : gastrointestinal manifestations and potential fecal-oral transmission", Gastroenterology, 158, pp.1518~1519 (2020)
- Mumm JN, "Urinary frequency as a possibly overlooked symptom in COVID-19 patients : does SARS-CoV-2 cause viral cystitis", Eur Urol, 78, pp.624~628 (2020)
- Hoffmann M, "SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor", Cell, 181, pp.271~280.e8 (2020)
- Liang X, "Is COVID-19 more severe in older men", Postgrad Med J, 96, pp.426~ (2020)
- Foo KT, "Pathophysiology of clinical benign prostatic hyperplasia", Asian J Urol, 4, pp.152~157 (2017)
- Xu H, "High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa", Int J Oral Sci, 12, pp.8~ (2020)
- Elaimeri A, "Effect of COVID 19 on lower urinary track symptoms in patients with benign prostatic hyperplasia", Res Sq (2021)[DOI]
- Nabeeh H, "Impact of COVID-19 pandemic on lower urinary tract symptoms in patients with benign prostatic hyperplasia and predictors of urine retention in such patients", Low Urin Tract Symptoms, 14, pp.41~46 (2022)
- Can O, "The effect of COVID-19 on lower urinary tract symptoms in elderly men", Int J Clin Pract, 75, pp.e14110~ (2021)
- Vosu J, "Is the risk of ibuprofen or other non-steroidal anti-inflammatory drugs increased in COVID-19", J Paediatr Child Health, 56, pp.1645~1646 (2020)
- Konig MF, "Preventing cytokine storm syndrome in COVID-19 using α-1 adrenergic receptor antagonists", J Clin Invest, 130, pp.3345~3347 (2020)
- Wambier CG, "Androgen sensitivity gateway to COVID-19disease severity", Drug Dev Res, 81, pp.771~776 (2020)
- Dhindsa S, "Association of circulating sex hormones with inflammation and disease severity in patients with COVID-19", JAMA Netw Open, 4, pp.e2111398~ (2021)
- Al-Kuraishy HM, "COVID-19 and phosphodiesterase enzyme type 5 inhibitors", J Microsc Ultrastruct, 8, pp.141~145 (2020)
- Giorgi M, "Phosphodiesterase inhibitors : could they be beneficial for the treatment of COVID-19", Int J Mol Sci, 21, pp.5338~ (2020)
- Mondaini Nicola, "Phosphodiesterase Type 5 Inhibitors and COVID-19: Are They Useful In Disease Management?", The World Journal of Men's Health, 38(3), pp.254~255 (2020), 대한남성과학회[DOI]
- Chinello P, "Sildenafil plasma concentrations in two HIV patients with pulmonary hypertension treated with ritonavir-boosted protease inhibitors", Curr HIV Res, 10, pp.162~164 (2012)
- Dinh DT, "Evidence for activation of the renin-angiotensin system in the human prostate : increased angiotensin II and reduced AT(1)receptor expression in benign prostatic hyperplasia", J Pathol, 196, pp.213~219 (2002)
- Dinh DT, "Identification, distribution, and expression of angiotensin II receptors in the normal human prostate and benign prostatic hyperplasia", Endocrinology, 142, pp.1349~1356 (2001)
- Izumi K, "Androgen receptor roles in the development of benign prostate hyperplasia", Am J Pathol, 182, pp.1942~1949 (2013)
- Wen S, "Stromal androgen receptor roles in the development of normal prostate, benign prostate hyperplasia, and prostate cancer", Am J Pathol, 185, pp.293~301 (2015)
- Madersbacher S, "Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement : a mini-review", Gerontology, 65, pp.458~464 (2019)
- Mahmudpour M, "COVID-19 cytokine storm : the anger of inflammation", Cytokine, 133, pp.155151~ (2020)
- Gottesman BL, "Incidence of new-onset type 1 diabetes among US children during the COVID-19 global pandemic", JAMA Pediatr, 176, pp.414~415 (2022)
- Metwally AA, "COVID-19-induced new-onset diabetes : trends and technologies", Diabetes, 70, pp.2733~2744 (2021)
- Breyer BN, "Hyperglycemia and insulin resistance and the risk of BPH", LUTS : an update of recent literature, 2014, pp.15, 462~